See more : Gravity (India) Limited (GRAVITY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of PT Phapros, Tbk (PEHA.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Phapros, Tbk, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Border Petroleum Limited (BOPFF) Income Statement Analysis – Financial Results
- OP Bancorp (OPBK) Income Statement Analysis – Financial Results
- Keyarch Acquisition Corporation (KYCH) Income Statement Analysis – Financial Results
- ACS, Actividades de Construcción y Servicios, S.A. (ACS.MC) Income Statement Analysis – Financial Results
- Khang Dien House Trading and Investment Joint Stock Company (KDH.VN) Income Statement Analysis – Financial Results
PT Phapros, Tbk (PEHA.JK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.phapros.co.id
About PT Phapros, Tbk
PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia. The company operates through Over the Counter (OTC), Ethical, Generic Drugs Bearing, and Toll Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others. The company also provides generic drug products for government institutions and hospitals, as well as produces drugs for other pharmaceutical industries; and offers medical devices. PT Phapros, Tbk also exports its products internationally. The company was founded in 1954 and is headquartered in Jakarta, Indonesia. PT Phapros, Tbk operates as a subsidiary of PT Kimia Farma (Persero) Tbk.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,014.13B | 1,168.47B | 1,051.44B | 980.56B | 1,105.42B | 1,022.97B | 1,002.13B | 816.13B | 691.25B | 578.14B | 521.61B | 529.75B | 470.67B |
| Cost of Revenue | 514.36B | 584.98B | 531.91B | 457.07B | 495.94B | 439.95B | 436.89B | 360.30B | 302.82B | 244.19B | 200.49B | 208.78B | 183.97B |
| Gross Profit | 499.77B | 583.50B | 519.53B | 523.49B | 609.48B | 583.02B | 565.24B | 455.83B | 388.43B | 333.95B | 321.12B | 320.97B | 286.70B |
| Gross Profit Ratio | 49.28% | 49.94% | 49.41% | 53.39% | 55.14% | 56.99% | 56.40% | 55.85% | 56.19% | 57.76% | 61.56% | 60.59% | 60.91% |
| Research & Development | 30.41B | 27.30B | 24.89B | 23.61B | 20.73B | 21.64B | 15.13B | 12.41B | 9.11B | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 15.14B | 12.94B | 9.14B | 12.76B | 16.32B | 12.64B | 11.91B | 9.12B | 7.13B | 7.40B | 6.36B | 6.99B | 6.63B |
| Selling & Marketing | 220.42B | 248.20B | 218.32B | 223.89B | 220.78B | 196.70B | 197.52B | 163.17B | 164.29B | 149.77B | 151.78B | 126.75B | 99.80B |
| SG&A | 402.40B | 261.14B | 227.47B | 236.65B | 237.10B | 209.34B | 209.44B | 172.29B | 171.42B | 157.17B | 158.14B | 133.74B | 106.44B |
| Other Expenses | -4.36B | 228.64B | 201.98B | 197.04B | 201.41B | 11.59B | 435.33M | 12.22B | 8.82B | 5.45B | 6.87B | 1.14B | 5.86B |
| Operating Expenses | 428.45B | 489.78B | 429.45B | 433.69B | 438.50B | 389.31B | 377.84B | 327.02B | 295.59B | 262.39B | 255.33B | 236.59B | 202.12B |
| Cost & Expenses | 942.81B | 1,074.76B | 961.36B | 890.76B | 934.44B | 829.26B | 814.73B | 687.32B | 598.41B | 506.57B | 455.82B | 445.37B | 386.09B |
| Interest Income | 629.90M | 665.80M | 2.38B | 2.09B | 673.79M | 960.05M | 1.21B | 246.91M | 153.55M | 120.98M | 289.13M | 195.08M | 891.53M |
| Interest Expense | 64.95B | 60.19B | 79.76B | 94.45B | 62.60B | 39.93B | 16.97B | 21.42B | 16.47B | 14.91B | 6.85B | 6.23B | 2.01B |
| Depreciation & Amortization | 48.82B | 53.14B | 55.68B | 52.41B | 41.84B | 25.53B | 17.39B | 14.21B | 1.90B | 1.94B | 5.81B | 5.40B | 5.34B |
| EBITDA | 120.77B | 154.83B | 148.33B | 210.94B | 234.34B | 248.05B | 206.60B | 157.37B | 115.36B | 88.26B | 68.82B | 100.80B | 96.24B |
| EBITDA Ratio | 11.91% | 9.82% | 10.36% | 17.59% | 18.02% | 21.58% | 19.10% | 17.62% | 14.47% | 13.78% | 13.00% | 18.72% | 20.66% |
| Operating Income | 71.32B | 98.77B | 92.10B | 158.53B | 192.66B | 193.71B | 187.40B | 128.81B | 92.83B | 71.57B | 66.27B | 84.90B | 84.57B |
| Operating Income Ratio | 7.03% | 8.45% | 8.76% | 16.17% | 17.43% | 18.94% | 18.70% | 15.78% | 13.43% | 12.38% | 12.71% | 16.03% | 17.97% |
| Total Other Income/Expenses | -63.66B | -59.53B | -77.38B | -74.98B | -41.92B | -16.51B | -1.03B | -7.08B | -6.80B | -10.35B | -10.11B | 4.28B | 4.32B |
| Income Before Tax | 7.66B | 41.50B | 12.89B | 64.08B | 129.66B | 177.57B | 171.35B | 121.74B | 86.04B | 61.83B | 56.16B | 89.17B | 88.89B |
| Income Before Tax Ratio | 0.76% | 3.55% | 1.23% | 6.54% | 11.73% | 17.36% | 17.10% | 14.92% | 12.45% | 10.69% | 10.77% | 16.83% | 18.89% |
| Income Tax Expense | 1.65B | 14.11B | 1.60B | 15.42B | 27.35B | 44.28B | 46.08B | 34.73B | 23.03B | 16.39B | 14.02B | 20.03B | 24.20B |
| Net Income | 5.96B | 28.07B | 11.07B | 48.49B | 102.03B | 132.31B | 125.27B | 87.00B | 63.01B | 45.33B | 42.11B | 69.16B | 64.70B |
| Net Income Ratio | 0.59% | 2.40% | 1.05% | 4.94% | 9.23% | 12.93% | 12.50% | 10.66% | 9.12% | 7.84% | 8.07% | 13.06% | 13.75% |
| EPS | 7.09 | 33.42 | 13.18 | 57.72 | 121.47 | 157.51 | 149.13 | 103.57 | 75.01 | 53.42 | 50.13 | 82.33 | 77.02 |
| EPS Diluted | 7.09 | 33.42 | 13.18 | 57.72 | 121.47 | 157.51 | 149.13 | 103.57 | 75.01 | 53.42 | 50.13 | 82.33 | 77.02 |
| Weighted Avg Shares Out | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M |
| Weighted Avg Shares Out (Dil) | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M | 840.00M |
Source: https://incomestatements.info
Category: Stock Reports